Commonly sold under the name of Daklinza, Dacalatasvir is the medicine which is prescribed to cure chronic hepatitis C virus (HCV) genotypes 1 and 3 infection and is mostly taken along with sofosbuvir or the HCV protease inhibitor asunaprevir and ribavirin. Decalatasvir is a new direct- acting antiviral drug that targets different steps of the Hepatitis C Virus lifecycle. How it works? Decalatasvir interferes with the protein with the help of which the virus reproduces, hence curbing its chance to spread any further in the body. It is strictly advised to take Dacalatasvir only with sofosbuvir, hence if a patient discontinues with sofosbuvir permanently, then he should definitely avoid dacalatasvir.